NCT06016036已完成3 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 156
- 试验地点
- 1
- 主要终点
- Difference in mean Hb concentration levels from baseline at weeks 7-9
研究概览
简要总结
This study is a phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of SAL-0951 in CKD-anemia patients in Non-dialysis, comprising 8 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 27 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-75 years old men and women;
- •40-100 kg weight;
- •The glomerular filtration rate value calculated by CKD-EPI formula is <60 mL/min/1.73 m^2 (stage 3, 4 or 5 of KDOQI chronic kidney disease) in non-dialyzed subjects with confirmed anemia of chronic kidney disease;
- •Ferritin > 100 g/L and TSAT > 20%;
- •No treatment with ESA was received at least 8 weeks before randomization, and the central laboratory hemoglobin value for the last two screening period (at least 6 days interval) >=80 g/L and <=105 g/L, and the change of absolute value of the two visits <=10g/L;
- •The investigators determined that dialysis or alternative kidney transplantation was not required throughout the trial;
- •Volunteer to participate in the trial and have an informed consent form signed.
排除标准
- •Blood pressure control was poor after regular drug therapy for more than 4 weeks before screening, SBP > 160mmHg or DBP > 100mmHg during screening;
- •Patients with severe complications of hepatobiliary system (AST or ALT > 2.5 ULN, TBiL > 1.5 ULN);
- •Acute kidney injury occurred 12 weeks before screening;
- •NYHA class III - IV heart failure or unstable angina;
- •Acute myocardial infarction, transient ischemic attack, cerebral infarction or pulmonary embolism, deep venous thrombosis occurred 6 months before randomization;
- •Patients requiring ophthalmologic treatment for diabetic eye disease, diabetic macular edema, or age-related macular degeneration, or patients with hypertrophic choroid or retinopathy;
- •Blood transfusion or red blood cell infusion within 3 months before screening;
- •Subjects received protein anabolic hormone, testosterone heptanoate, or methadone within 3 month before screening
- •Severe hyperparathyroidism (iPTH>=500pg/mL);
- •Patients with HIV, HCV or Treponema pallidum antibody positive, or HBsAg positive with HBV DNA>=1000 U/mL;
- •Severe active infection (active tuberculosis, fungal infection, etc.), systemic blood disease (myelodysplastic syndrome, aplastic anemia), or hemolytic anemia, or hemorrhagic anemia;
- •A history of malignancy, exceptions: tumors determined to be cured or in remission for 5 years, skin basal cell or squamous cell carcinomas that have been radically resected, or carcinomas in situ of any site;
- •Chronic inflammatory disease other than glomerulonephritis that may affect red blood cell production, such as systemic lupus erythematosus, rheumatoid arthritis, celiac disease, etc.;
- •A history of severe allergy to medications (e.g. anaphylactic shock) or allergy to other HIF-PH inhibitors;
- •A history of drug or alcohol abuse in the past two years;
- •Participated in clinical trials of any other drug or medical device within 3 months before screening, or plan to participate in any other clinical trials of drug or medical device during the trial;
- •SAL-0951 products or other HIF-PH inhibitors were used before screening;
- •Female during pregnancy or lactation;
- •From the time the informed consent form was sighed to the end of the study, woman of childbearing age who does not agree to use effective contraception, or man whose sexual partner is a woman of childbearing age (Effective methods of contraception include transdermal patches, oral drugs, implantable or injectable contraceptives, abstinence or birth control);
- •Medical conditions that the investigators believe may pose a safety risk to subjects, or confuse efficacy or safety evaluations, or interfere with subject participation.
研究组 & 干预措施
SAL-0951
Experimental
干预措施: SAL-0951 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Difference in mean Hb concentration levels from baseline at weeks 7-9
时间窗: Baseline and week 7-9
Change From Baseline in mean Hb concentration levels at week 7-9
次要结局
- Double-blind phase：By week 9, the cumulative proportion of subjects whose Hb increased by ≥10 g/L and whose Hb reached ≥100g/L(Week 9)
- double-blind phase：The cumulative percentage of subjects who achieved Hb response at any time from treatment to week 9(Baseline to week 9)
- Double-blind phase：Proportion of subjects with average Hb level ≥100 g/L at week 7-9(Week 7-9)
- Double-blind phase：Proportion of average Hb concentration ≥100g/L and ≤120g/L in week 9(Week 9)
- Double-blind phase：By week 9, the cumulative proportion of Hb > 130 g/L(Week 9)
- Double-blind phase：Proportion of subjects receiving intravenous iron at week 9(Week 9)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)Raynaud's Phenomenon Secondary to Systemic SclerosisNCT04040322Civi Biopharma, Inc.198
已完成
3 期
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by MetforminDiabetes Mellitus, Type 2NCT05801627Shenzhen Salubris Pharmaceuticals Co., Ltd.408
终止
3 期
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic SclerosisNCT03398837Corbus Pharmaceuticals Inc.365
已完成
3 期
Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisDermatomyositisNCT03813160Corbus Pharmaceuticals Inc.176
已完成
3 期
A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated PainEndometriosisNCT06076486Nanjing Chia-tai Tianqing Pharmaceutical202